

Biosimilars Workshop

- Regulatory issues
- Pharmacoeconomic aspects

**DGRA Workshop for members
on September 26, 2013
at Paul-Ehrlich-Institut,
Paul-Ehrlich-Str. 51-59, 63225 Langen**

9:30 a.m. – 5:00 p.m.

Moderation: Dr. Ulrich Granzer, Granzer Consulting

**Speakers: Dr. Marie-Christine Bielsky,
Medicines and Healthcare Products Regulatory Agency, MHRA UK
Dr. Brigitte Brake, Bonn
Dr. Pascale Burtin, Sandoz
Dr. Pekka Kurki, Finnish Medicines Agency
Dr. Gabriele Reichmann, Langen
Prof. Burkhard Sträter, Law Firm Sträter Lawyers**

Programme:

09:30 a.m. I. Overarching Guideline - the concept of a “Biosimilar medicinal product”

- Revision of “Guideline on similar medicinal products”
- Selection of reference products

Dr. Pekka Kurki, Finnish Medicines Agency,

Former Chair of the Biosimilar Medicinal Products Working Party (BMWP) EMA

10:30 a.m. . coffee break

11:00 a.m. II. From Comparability to Biosimilarity –quality aspects

- Requirements of quality dossiers
- Comparative characterization – which differences are acceptable?

Dr. Brigitte Brake, Bonn

11:45 a.m. III. Development of biosimilar products from the substance category of monoclonal antibodies

- Non-clinical aspects

Dr. Gabriele Reichmann, Langen

Expert of the Biosimilar Medicinal Products Working Party (BMWP) EMA

12:30 p.m. Lunch break

1:30 p.m. IV. The experience with biosimilars - how does it influence current clinical requirements

- Acceptance of surrogate parameters with regard to efficacy
- Patient population in pivotal studies

Dr. Marie-Christine Bielsky, MHRA UK

Member of the Biosimilar Medicinal Products Working Party (BMWP) EMA

2:15 p.m. V. Industrial perspective and experience

- Sandoz Biosimilar experience and concepts
- Technical versus Clinical development
- Challenges encountered
- Harmonization between regulatory jurisdictions
- Pharmacovigilance and risk management
- Education of medical community

Dr. Pascale Burtin, Sandoz

3:00 p.m. coffee break

3:30 p.m. VI. Traceability, substitution, impact on Reimbursement financed by the German Statutory Health Insurance System (GKV)

- Identification of products in ADR reporting - requirements acc. Art. 102 (Directive 2001/83)
- Additional monitoring black triangle for biosimilars?

Prof. Burkhard Sträter, Kanzlei Sträter

4:15 p.m. VII. Panel discussion

all speakers and participants

around 5:00 p.m. end

(Program subject to change without prior notice)

further information

p.t.o.

Date:

Thursday, September 26, 2013

Start: 9:30 a.m.

End: around 5:00 p.m.

Venue

Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59
D-63225 Langen, phone: 06103 – 77-0

Cost contribution:

For DGRA members and students of
M.D.R.A. Course 14/15: € 270

The Casino of DFS near by (DFS Deutsche
Flugsicherung - German Air Traffic Services)
is open for lunch (not included).

Cancellations terms:

Up to two weeks before the first day of the
conference (September 12,-2013): € 50; up to
one week before the first day of the
conference (September 19, 2013): 50% of fee;
late cancellations: full conference fee if a
substitute participant (DGRA member)
cannot be put forward.

In the event of cancellation by the organizer,
any fees already paid will be fully
reimbursed.

Workshop language:

English

Room reservation:

A limited number of rooms is available for
participants at special rates in the hotels listed
below. When making reservations please
refer to this event.

- Hotel Steigenberger, Langen
Phone: 0049 - 06103 - 9720
- Achat Comfort Hotel, Langen
Phone.: 0049 – 6103 756 0

Further hotel reservations can be made
directly via internet portals e.g.
[www.carisma-engine .de](http://www.carisma-engine.de), www.hrs.de

Note:

Photographers will accompany the workshop.
Some photographic material will be
published.

Workshop documents will include a list of
participants.

Registration:

As a DGRA member please use the
application form at www.dgra.de or contact
us at info@dgra.de

DGRA-Office
Adenauerallee 15
D-53111 Bonn
phone: 0228 - 368 26 46
fax: 0228 - 368 26 47
E-mail: info@dgra.de